Jazz bets on epilepsy again by acquiring Actio for $820M upfront
Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug. The deal further solidifies Jazz’s ...
Jazz Pharmaceuticals CEO Renee Gala (L) and Actio Biosciences CEO David Goldstein August 10, 2026 09:45 AM EDT Deals Jazz bets on epilepsy again by acquiring Actio for $820M upfront Kyle LaHucik Biotech Correspondent Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that